Results 91 to 100 of about 8,733,364 (311)
Advanced ScienceDespite significant research progress, tumor heterogeneity remains elusive, and its complexity poses a barrier to anticancer drug discovery and cancer treatment.
Yoo‐mi Choi +9 more
doaj +1 more source
Molecular Oncology, EarlyView.The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim +17 more
wiley +1 more source
Drug Court Process Evaluation Report, February 2008 [PDF]
, 2008 The Iowa Consortium for Substance Abuse Research and Evaluation conducted a process evaluation in 2007 on the seven adult and juvenile drug courts existing in Iowa in 2003.
core
Preclinical Models of Restenosis and Their Application in the Evaluation of Drug-Eluting Stent Systems [PDF]
Veterinary Pathology, 2009 Coronary arterial disease (CAD) is the leading cause of death in the United States, the European Union, and Canada. Percutaneous coronary intervention (PCI) has revolutionized the treatment of CAD, and it is the advent of drug-eluting stent (DES) systems that has effectively allayed much of the challenge of restenosis that has plagued the success of ...
openaire +2 more sources
Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer
Molecular Oncology, EarlyView.Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba +5 more
wiley +1 more source
Drug development (preclinical and clinical) for tropical diseases has increased.
, 2018 Drug development (preclinical and clinical) for tropical diseases has increased.
Kathleen L. Miller (5616644) +2 more
core +1 more source
Mechanisms of Cell Death Induced by Cannabidiol Against Tumor Cells: A Review of Preclinical Studies
PlantsCommonly known as marijuana or hemp, Cannabis sativa L. (Cannabaceae), contains numerous active compounds, particularly cannabinoids, which have been extensively studied for their biological activities.
Edilene S. A. Melo +8 more
doaj +1 more source
Molecular Oncology, EarlyView.LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David +12 more
wiley +1 more source
Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy
Molecular Oncology, EarlyView.LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir +9 more
wiley +1 more source
Human skin-on-a-chip for mpox pathogenesis studies and preclinical drug evaluation. [PDF]
Trends Pharmacol Sci, 2023 Zhu J, Abaci HE.
europepmc +1 more source